Effects of alpha 2-plasmin inhibitor on plasminogen activation by staphylokinase/plasminogen complex. 1994

K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
Department of Physiology, Kinki University School of Medicine, Osakasayama, Japan.

Using a stable cross-linked SAK/plg complex, the effects of alpha 2-plasmin inhibitor on plasminogen activation by SAK were investigated. alpha 2-Plasmin inhibitor inhibited dose-dependently plasminogen activation by the SAK/plg complex. When FCB-2 or EACA was added to the reaction mixture of SAK/plg complex and alpha 2-plasmin inhibitor, the inhibitory activity of alpha 2-plasmin inhibitor was abolished and the enzymatic activity of the complexes was restored. alpha 2-Plasmin inhibitor inhibited the activity of the SK/plg complex, but neither FCB-2 nor EACA restored the plasminogen activator activity in the mixture of SK/plg complex and alpha 2-plasmin inhibitor. Using 125I-labeled SAK/plg complex or SK/plg complex, the reaction of the complex with alpha 2-plasmin inhibitor was analyzed. The SAK/plg complex produced a new complex with alpha 2-plasmin inhibitor. The formation of a new high molecular weight complex with alpha 2-plasmin inhibitor was abolished by both EACA or FCB-2. With regard to the SK/plg complex, neither EACA nor FCB-2 suppressed the complex formation with alpha 2-plasmin inhibitor. These findings indicate that the SAK/plg complex binds to fibrin, and that this complex expresses plasminogen activator activity without being affected by alpha 2-plasmin inhibitor.

UI MeSH Term Description Entries
D008666 Metalloendopeptidases ENDOPEPTIDASES which use a metal such as ZINC in the catalytic mechanism. Metallo-Endoproteinases,Metalloendopeptidase
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010958 Plasminogen Precursor of plasmin (FIBRINOLYSIN). It is a single-chain beta-globulin of molecular weight 80-90,000 found mostly in association with fibrinogen in plasma; plasminogen activators change it to fibrinolysin. It is used in wound debriding and has been investigated as a thrombolytic agent. Profibrinolysin,Glu-Plasminogen,Glutamic Acid 1-Plasminogen,Glutamyl Plasminogen,1-Plasminogen, Glutamic Acid,Glu Plasminogen,Glutamic Acid 1 Plasminogen,Plasminogen, Glutamyl
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000979 alpha-2-Antiplasmin A member of the serpin superfamily found in plasma that inhibits the lysis of fibrin clots which are induced by plasminogen activator. It is a glycoprotein, molecular weight approximately 70,000 that migrates in the alpha 2 region in immunoelectrophoresis. It is the principal plasmin inactivator in blood, rapidly forming a very stable complex with plasmin. alpha 2-Plasmin Inhibitor,Serpin F2,alpha(2)-Plasmin Inhibitor,alpha-2 Antiplasmin,alpha 2 Antiplasmin,alpha 2 Plasmin Inhibitor
D015119 Aminocaproic Acid An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. 6-Aminocaproic Acid,6-Aminohexanoic Acid,epsilon-Aminocaproic Acid,Amicar,CY-116,Capralense,Capramol,Caproamin,Caprocid,Caprolest,Epsamon,Epsikapron,Hemocaprol,Hexalense,6 Aminocaproic Acid,6 Aminohexanoic Acid,CY 116,CY116,epsilon Aminocaproic Acid

Related Publications

K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
April 1994, Journal of biochemistry,
K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
May 1993, The Journal of biological chemistry,
K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
September 1999, Nihon rinsho. Japanese journal of clinical medicine,
K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
November 1983, Blood,
K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
March 1995, Nihon rinsho. Japanese journal of clinical medicine,
K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
July 1989, Biochemical and biophysical research communications,
K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
October 2000, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis,
K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
January 1989, Journal of neurosurgery,
K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
July 2008, European journal of haematology,
K Okada, and T Nonaka, and H Matsumoto, and H Fukao, and S Ueshima, and O Matsuo
February 1960, Nature,
Copied contents to your clipboard!